N.G. TSAREVA, O.N. YASHKINA, O.V. BORISOVA

Samara State Medical University, Samara

Contact details:

Tsareva N.G. — Assistant Lecturer of the Department of Children’s Infections

Address: 89 Chapayevskaya St., 443099 Samara, Russian Federation, tel.: +7 (846) 994-75-38, e-mail: n.g.careva@samsmu.ru

The issues of early diagnosis and rational therapy of community-acquired pneumonia in children remain relevant in pediatric practice.

The purpose — to analyze the epidemiological and clinical features of community-acquired pneumonia in children in 2022–2023.

Material and methods. The study was conducted at the Children’s Polyclinic Department of Samara City Polyclinic No. 10 from January 2022 to December 2023. Retrospectively, we studied discharge summaries from medical records of children diagnosed with community-acquired pneumonia.

Results. In 2023, there were 4 times more diagnosed cases of community-acquired pneumonia compared to 2022. We marked seasonality of the disease in autumn and winter. Randomized by age, the age group from 3 to 7 years prevailed. The prevalence of Mycoplasma pneumoniae was the highest among children aged 10–17 years. In the etiological structure of community-acquired pneumonias in 2022, viruses prevailed. In 2023, atypical pathogens were detected in most cases: Mycoplasma pneumoniae or its coinfection with other pathogens.

Conclusions. In 2023, there was a 4-fold increase in the incidence of community-acquired pneumonia among children. Atypical pneumonias caused by Mycoplasma pneumoniae and coinfections with other pathogens prevailed. All hospitalized children with community-acquired pneumonia must be tested for atypical pathogens.

Key words: community-acquired pneumonia, mycoplasma infection, children, epidemiology, clinical features.

REFERENCES

1. Selvi M., Vaithilingan S. Childhood pneumonia in low- and middle-income countries: a systematic review of prevalence, risk factors, and healthcare-seeking behaviors. Cureus, 2024, vol. 16 (4), p. 57636. doi: 10.7759/cureus.57636
2. Vaughn V.M., Dickson R.P., Horowitz J.K., Flanders S.A. Community-acquired pneumonia: a review. JAMA, 2024, vol. 332 (15), pp. 1282–1295. doi: 10.1001/jama.2024.14796
3. Meyer Sauteur P.M., Beeton M.L., Uldum S.A., Bossuyt N., Vermeulen M., Loens K. ESGMAC–MyCOVID study team. Mycoplasma pneumoniae detections before and during the COVID-19 pandemic: results of a global survey, 2017 to 2021. Euro Surveill, 2022, vol. 27 (19), p. 2100746. DOI: 10.2807/1560-7917
4. Goretzki S.C., van der Linden M., Itzek A., Hühne T., Adelmann R.O., Ala Eldin F. et al. Outbreak of severe community-acquired bacterial infections among children in North Rhine-Westphalia (Germany), October to December 2022. Infection, 2024, vol. 52 (3), pp. 1099–1111. doi: 10.1007/s15010-023-02165-x
5. Wang X., Li M., Luo M., Luo Q., Kang L., Xie H. et al. Mycoplasma pneumonia triggers pneumonia epidemic in autumn and winter in Beijing: a multicentre, population-based epidemiological study between 2015 and 2020. Emerg. Microbes. Infect, 2022, vol. 11 (1), pp. 1508–1517. doi: 10.1080/ 22221751.2022.2078228
6. Quach A., Spence H., Nguyen C., Graham S.M., von Mollendorf C., Mulholland K., Russell F.M. Slow progress towards pneumonia control for children in low-and-middle income countries as measured by pneumonia indicators: A systematic review of the literature. J GlobHealth, 2022, (12), p. 10006. doi: 6.10.7189/jogh.12.10006
7. Xu Y., Yang C., Sun P., Zeng F., Wang Q., Wu J. et al. Epidemic features and megagenomic analysis of childhood Mycoplasma pneumonia post COVID-19 pandemic: a 6-year study in southern China. Emerg. Microbes Infect, 2024, vol. 13 (1), p. 2353298. doi: 10.1080/22221751.2024.2353298
8. Savenkova M.S., Savenkov M.P. Actual issues of treatment of intracellular infections in children. RMZh. Mat’ i ditya, 2020, vol. 3, no. 4, pp. 326–335 (in Russ.). DOI: 10.32364/2618-8430-2020-3-4-326-335
9. Yun K.W. Community-acquired pneumonia in children: updated perspectives on its etiology, diagnosis, and treatment. Clin. Exp. Pediatr, 2024, vol. 67 (2), rr. 80–89. doi: 10.3345/cep.2022.01452
10. Li L., Guo P., Ma J., Sun H., Mei S. Impact of COVID-19 on the epidemiological features of Mycoplasma pneumoniae infection in children with community acquired pneumonia in Henan, China. Microbiol. Spectr, 2023, vol. 14 (1), r. e0491122. DOI: 10.1128/spectrum.04911-22
11. Chen J., Zhang J., Lu Z., Chen Y., Huang S., Li H. et al. Mycoplasma pneumoniae among Chinese outpatient children with mild respiratory tract infections during the coronavirus disease 2019 pandemic. Microbiol. Spectr, is. 10, rr. e01550-21. doi: 10.1128/spectrum.01550-21
12. Rueda Z.V., Aguilar Y., Maya M.A., López L., Restrepo A., Garcés C. et al. Etiology and the challenge of diagnostic testing of community-acquired pneumonia in children and adolescents. BMC Pediatr, 2022, vol. 22 (1), r. 169. doi: 10.1186/s12887-022-03235-z
13. Klinicheskie rekomendatsii MZ RF «Vnebol’nichnaya pnevmoniya u detey». 2022, [Clinical guidelines of the Ministry of Health of the Russian Federation «Community-acquired pneumonia in children». 2022], available at: https://www.antibiotic.ru/iacmac/news/klinicheskie-rekomendacii-vnebolnichnaya-pnevmoniya-u-detej/ (accessed on: 24.02.2025).
14. Zeynebekova A.B., Dyusenova S.B., Kizatova S.T., Sarmankulova G.A., Kir’yanova T.A., Tlegenova K.S. et al. Features of community-acquired pneumonia in children depending on vaccination. Infektsionnye bolezni: novosti, mneniya, obuchenie, 2023, vol. 12, no. 2, pp. 69–74 (in Russ.). DOI: 10.33029/2305-3496-2023-12-2-69-74
15. Shilova A.A. Current experience of using macrolides in foreign pediatric practice. Mezhdunarodnyy nauchno-issledovatel’skiy zhurnal, 2022, vol. 9, no. 123, pp. 1–4 (in Russ.). DOI: 10.23670/IRJ.2022.123.34